Panbela Therapeutics Past Earnings Performance
Past criteria checks 0/6
Panbela Therapeutics's earnings have been declining at an average annual rate of -36.3%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-36.3%
Earnings growth rate
8.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Panbela Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -35 | 6 | 10 |
| 30 Sep 22 | 0 | -34 | 6 | 9 |
| 30 Jun 22 | 0 | -31 | 5 | 8 |
| 31 Mar 22 | 0 | -12 | 5 | 7 |
| 31 Dec 21 | 0 | -10 | 5 | 5 |
| 30 Sep 21 | 0 | -7 | 4 | 4 |
| 30 Jun 21 | 0 | -7 | 5 | 4 |
| 31 Mar 21 | 0 | -5 | 4 | 3 |
| 31 Dec 20 | 0 | -5 | 3 | 3 |
| 30 Sep 20 | 0 | -5 | 3 | 3 |
| 30 Jun 20 | 0 | -5 | 2 | 3 |
| 31 Mar 20 | 0 | -6 | 2 | 3 |
| 31 Dec 19 | 0 | -6 | 2 | 2 |
| 30 Sep 19 | 0 | -6 | 2 | 2 |
| 30 Jun 19 | 0 | -6 | 2 | 2 |
| 31 Mar 19 | 0 | -6 | 2 | 2 |
| 31 Dec 18 | 0 | -6 | 2 | 2 |
| 30 Sep 18 | 0 | -7 | 3 | 2 |
| 30 Jun 18 | 0 | -8 | 3 | 2 |
| 31 Mar 18 | 0 | -7 | 3 | 2 |
| 31 Dec 17 | 0 | -10 | 3 | 3 |
| 30 Sep 17 | 0 | -10 | 4 | 3 |
| 30 Jun 17 | 0 | -10 | 4 | 3 |
| 31 Mar 17 | 0 | -10 | 3 | 3 |
| 31 Dec 16 | 0 | -5 | 3 | 3 |
| 30 Sep 16 | 0 | -4 | 1 | 3 |
Quality Earnings: X70 is currently unprofitable.
Growing Profit Margin: X70 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: X70 is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.
Accelerating Growth: Unable to compare X70's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: X70 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: X70's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.